(Q33787731)

English

Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

zoledronic acid

1 reference

based on heuristic

inferred from title

Pamela J Atherton

3

object named as

Pamela J Atherton

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

4

object named as

Edith A Perez

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

author name string

Stephanie L Hines

1

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Jeff A Sloan

2

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Shaker R Dakhil

5

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

David B Johnson

6

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Pavan S Reddy

7

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Robert J Dalton

8

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Bassam I Mattar

9

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Charles L Loprinzi

10

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

publication date

15 January 2010

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

19

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

92-96

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2854212

28 July 2018

FRAX and the assessment of fracture probability in men and women from the UK

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2854212

28 July 2018

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2854212

28 July 2018

Aromatase inhibitors and bone loss

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2854212

28 July 2018

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2854212

28 July 2018

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2854212

28 July 2018

Risedronate: a clinical review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2854212

28 July 2018

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2854212

28 July 2018

Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2854212

30 October 2018

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2854212

30 October 2018

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2854212

30 October 2018

Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2854212

30 October 2018

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2854212

30 October 2018

Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2854212

30 October 2018

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2854212

30 October 2018

Intravenous zoledronic acid in postmenopausal women with low bone mineral density

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2854212

30 October 2018

Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2854212

30 October 2018

Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2854212

30 October 2018

Does calcium supplementation prevent postmenopausal bone loss? A double-blind, controlled clinical study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20079640

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevention of postmenopausal osteoporosis. A comparative study of exercise, calcium supplementation, and hormone-replacement therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20079640

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230)

1 reference

https://pubmed.ncbi.nlm.nih.gov/20079640

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17

1 reference

https://pubmed.ncbi.nlm.nih.gov/20079640

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

1 reference

https://pubmed.ncbi.nlm.nih.gov/20079640

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20079640

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.BREAST.2009.12.001

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33787731&oldid=1653184981"